OGI
Organigram Global Inc.
Drug Manufacturers - Specialty & Generic
Market Cap$186M
5Y Perf.-80.2%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
OGI vs DBVT
Revenue, margins, valuation, and 5-year total return — side by side.
DBVT
DBV Technologies S.A.
Biotechnology
Market Cap$1712.35T
5Y Perf.-58.8%
OGI vs DBVT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | OGI | DBVT |
|---|---|---|
| Industry | Drug Manufacturers - Specialty & Generic | Biotechnology |
| Market Cap | $186M | $1712.35T |
| Revenue (TTM) | $280M | $0.00 |
| Net Income (TTM) | $18M | $-168M |
| Gross Margin | 28.9% | — |
| Operating Margin | -10.2% | — |
| Forward P/E | 9.8x | — |
| Total Debt | $9M | $22M |
| Cash & Equiv. | $28M | $194M |
OGI vs DBVT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
OGI
DBVT
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Organigram Global I… (OGI) | 100 | 19.8 | -80.2% |
| DBV Technologies S.… (DBVT) | 100 | 41.2 | -58.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: OGI vs DBVT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: OGI leads in 3 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. DBV Technologies S.A. is the stronger pick specifically for capital preservation and lower volatility and recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
OGI
Organigram Global Inc.
The Growth Play
OGI carries the broadest edge in this set and is the clearest fit for growth exposure.
- Rev growth 16.4%, EPS growth 70.8%, 3Y rev CAGR 8.5%
- 16.4% revenue growth vs DBVT's -100.0%
- 6.5% margin vs DBVT's 0.3%
Best for: growth exposure
DBVT
DBV Technologies S.A.
The Income Pick
DBVT is the clearest fit if your priority is income & stability and long-term compounding.
- Dividend streak 0 yrs, beta 1.26
- -87.0% 10Y total return vs OGI's -95.6%
- Lower volatility, beta 1.26, Low D/E 12.8%, current ratio 3.67x
Best for: income & stability and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | OGI | 16.4% revenue growth vs DBVT's -100.0% |
| Quality / Margins | OGI | 6.5% margin vs DBVT's 0.3% |
| Stability / Safety | DBVT | Beta 1.26 vs OGI's 1.33 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | DBVT | +110.4% vs OGI's +23.2% |
| Efficiency (ROA) | OGI | 3.4% ROA vs DBVT's -89.0% |
OGI vs DBVT — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2025
Segment breakdown not available.
OGI vs DBVT — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLOGILAGGINGDBVT
DBVTDBV Technologies S.A.
2leads
OGIOrganigram Global Inc.
2leads
6 Total Categories
CATEGORYLEADERvs DBVTMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
OGI1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
OGI5/7
Total Returns1Y, 3Y, 5Y total returns with dividends
DBVT6/6
Risk & VolatilityBeta, volatility, and downside exposure
DBVT2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
OGI leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
OGI and DBVT operate at a comparable scale, with $280M and $0 in trailing revenue.
| Metric | OGIOrganigram Global… | DBVTDBV Technologies … |
|---|---|---|
| RevenueTrailing 12 months | $280M | $0 |
| EBITDAEarnings before interest/tax | -$9M | -$112M |
| Net IncomeAfter-tax profit | $18M | -$168M |
| Free Cash FlowCash after capex | -$36M | -$151M |
| Gross MarginGross profit ÷ Revenue | +28.9% | — |
| Operating MarginEBIT ÷ Revenue | -10.2% | — |
| Net MarginNet income ÷ Revenue | +6.5% | — |
| FCF MarginFCF ÷ Revenue | -13.0% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | +48.6% | — |
| EPS Growth (YoY)Latest quarter vs prior year | +175.0% | +91.5% |
OGI leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — OGI and DBVT each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | OGIOrganigram Global… | DBVTDBV Technologies … |
|---|---|---|
| Market CapShares × price | $186M | $1712.35T |
| Enterprise ValueMkt cap + debt − cash | $172M | $1712.35T |
| Trailing P/EPrice ÷ TTM EPS | -13.45x | -0.76x |
| Forward P/EPrice ÷ next-FY EPS est. | 9.82x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 1.37x | — |
| Price / BookPrice ÷ Book value/share | 0.69x | 0.66x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — OGI and DBVT each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
OGI leads this category, winning 5 of 7 comparable metrics.
Profitability & Efficiency
OGI delivers a 4.9% return on equity — every $100 of shareholder capital generates $5 in annual profit, vs $-130 for DBVT. OGI carries lower financial leverage with a 0.03x debt-to-equity ratio, signaling a more conservative balance sheet compared to DBVT's 0.13x. On the Piotroski fundamental quality scale (0–9), DBVT scores 4/9 vs OGI's 2/9, reflecting mixed financial health.
| Metric | OGIOrganigram Global… | DBVTDBV Technologies … |
|---|---|---|
| ROE (TTM)Return on equity | +4.9% | -130.2% |
| ROA (TTM)Return on assets | +3.4% | -89.0% |
| ROICReturn on invested capital | -17.8% | — |
| ROCEReturn on capital employed | -16.0% | -145.7% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 4 |
| Debt / EquityFinancial leverage | 0.03x | 0.13x |
| Net DebtTotal debt minus cash | -$19M | -$172M |
| Cash & Equiv.Liquid assets | $28M | $194M |
| Total DebtShort + long-term debt | $9M | $22M |
| Interest CoverageEBIT ÷ Interest expense | — | -189.82x |
OGI leads this category, winning 5 of 7 comparable metrics.
Total Returns (Dividends Reinvested)
DBVT leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in DBVT five years ago would be worth $3,090 today (with dividends reinvested), compared to $1,255 for OGI. Over the past 12 months, DBVT leads with a +110.4% total return vs OGI's +23.2%. The 3-year compound annual growth rate (CAGR) favors DBVT at 6.2% vs OGI's -13.1% — a key indicator of consistent wealth creation.
| Metric | OGIOrganigram Global… | DBVTDBV Technologies … |
|---|---|---|
| YTD ReturnYear-to-date | -20.2% | +4.9% |
| 1-Year ReturnPast 12 months | +23.2% | +110.4% |
| 3-Year ReturnCumulative with dividends | -34.3% | +19.7% |
| 5-Year ReturnCumulative with dividends | -87.5% | -69.1% |
| 10-Year ReturnCumulative with dividends | -95.6% | -87.0% |
| CAGR (3Y)Annualised 3-year return | -13.1% | +6.2% |
DBVT leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
DBVT leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
DBVT is the less volatile stock with a 1.26 beta — it tends to amplify market swings less than OGI's 1.33 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. DBVT currently trades 76.3% from its 52-week high vs OGI's 61.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | OGIOrganigram Global… | DBVTDBV Technologies … |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.33x | 1.26x |
| 52-Week HighHighest price in past year | $2.24 | $26.18 |
| 52-Week LowLowest price in past year | $1.10 | $7.53 |
| % of 52W HighCurrent price vs 52-week peak | +61.6% | +76.3% |
| RSI (14)Momentum oscillator 0–100 | 46.8 | 48.1 |
| Avg Volume (50D)Average daily shares traded | 632K | 252K |
DBVT leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates OGI as "Buy" and DBVT as "Buy".
| Metric | OGIOrganigram Global… | DBVTDBV Technologies … |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | — | $46.33 |
| # AnalystsCovering analysts | 5 | 15 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | 0 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
OGI leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). DBVT leads in 2 (Total Returns, Risk & Volatility). 1 tied.
Best OverallOrganigram Global Inc. (OGI)Leads 2 of 6 categories
Loading custom metrics...
OGI vs DBVT: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is OGI or DBVT a better buy right now?
Analysts rate Organigram Global Inc.
(OGI) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — OGI or DBVT?
Over the past 5 years, DBV Technologies S.
A. (DBVT) delivered a total return of -69. 1%, compared to -87. 5% for Organigram Global Inc. (OGI). Over 10 years, the gap is even starker: DBVT returned -87. 0% versus OGI's -95. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — OGI or DBVT?
By beta (market sensitivity over 5 years), DBV Technologies S.
A. (DBVT) is the lower-risk stock at 1. 26β versus Organigram Global Inc. 's 1. 33β — meaning OGI is approximately 5% more volatile than DBVT relative to the S&P 500. On balance sheet safety, Organigram Global Inc. (OGI) carries a lower debt/equity ratio of 3% versus 13% for DBV Technologies S. A. — giving it more financial flexibility in a downturn.
04Which is growing faster — OGI or DBVT?
On earnings-per-share growth, the picture is similar: Organigram Global Inc.
grew EPS 70. 8% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — OGI or DBVT?
DBV Technologies S.
A. (DBVT) is the more profitable company, earning 0. 0% net margin versus -9. 6% for Organigram Global Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: DBVT leads at 0. 0% versus -34. 1% for OGI. At the gross margin level — before operating expenses — OGI leads at 3. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — OGI or DBVT?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is OGI or DBVT better for a retirement portfolio?
For long-horizon retirement investors, DBV Technologies S.
A. (DBVT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 26)). Both have compounded well over 10 years (DBVT: -87. 0%, OGI: -95. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between OGI and DBVT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: OGI is a small-cap high-growth stock; DBVT is a mega-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.